Hookipa Pharma

hookipapharma.com

Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. Hookipa´s TheraT and Vaxwave platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT are unprecedented in the field and have the potential to transform active immune-therapy in cancers. Hookipa has completed the active phase of a Phase 1 trial of a Vaxwave-based vaccine against cytomegalovirus (CMV) and is finalizing clinical development plans for TheraT in Human Papilloma Virus (HPV)- related head and neck cancers.